We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Edwards Lifesciences' Q1 Earnings on Deck: Here's What to Expect
Read MoreHide Full Article
Key Takeaways
Edwards Lifesciences is set to report Q1 2026 results on April 23, with revenues seen rising 12.9%.
EW's TAVR unit likely drove growth, fueled by SAPIEN adoption and strong U.S. treatment trends.
EW's TMTT segment gains traction as PASCAL, EVOQUE and SAPIEN M3 support expanding valve therapies.
Edwards Lifesciences Corp. (EW - Free Report) is scheduled to report first-quarter 2026 results on April 23, after market close.
In the last reported quarter, the company’s adjusted earnings per share of 58 cents missed the Zacks Consensus Estimate by 6.45%. Its earnings beat estimates in three of the trailing four quarters and missed in one, the average surprise being 5.46%.
EW’s Q1 Estimates
The Zacks Consensus Estimate for revenues is pegged at $1.59 billion, suggesting 12.9% growth from the year-ago reported figure.
The Zacks Consensus Estimate for earnings is pinned at 72 cents per share, indicating a 12.5% rise from the year-ago reported number.
Estimate Revision Trend Ahead of Edwards’ Q1 Earnings
Estimates for earnings have remained unchanged at 72 cents per share in the past 30 days.
Here’s a brief overview of the company’s progress ahead of this announcement.
Factors at Play
In the first quarter of 2026, the Transcatheter Aortic Valve Replacement (“TAVR”) arm is likely to have delivered strong performance, supported by clinicians' elevated focus on SAPIEN therapy and proactive disease management for patients with severe aortic stenosis.
In the United States, growth appears to have been driven by a strong focus on the timely treatment of patients with severe aortic stenosis, supported by a growing body of high-quality clinical evidence for the SAPIEN platform and increased adoption of the company’s SAPIEN 3 Ultra RESILIA. Progress is also likely to have been supported by CMS’ decision to formally reconsider the NCD for TAVR.
In the previous quarter, results in Europe reflected solid underlying procedure growth and consistent regional execution, supported by updated European Society of Cardiology and European Association for Cardiothoracic Surgery guidelines that are reshaping clinical discussions. We expect these trends to have persisted in the first quarter as well.
Per the Zacks Consensus Estimate, TAVR sales are expected to be $1.16 billion, implying a 10.5% year-over-year increase.
In the Transcatheter Mitral and Tricuspid Therapies (“TMTT”) segment, strength in the portfolio of repair and replacement technologies for both Mitral and Tricuspid valves is likely to have supported Edwards’ performance in first-quarter 2026. The PASCAL and EVOQUE systems are expected to have gained traction globally.
Also, with the addition of SAPIEN M3 mitral valve replacement system — the first transcatheter therapy utilizing a transseptal approach — Edwards is uniquely positioned to have met the broad and diverse needs of patients with mitral and tricuspid valve diseases.
Edwards Lifesciences Corporation Price and EPS Surprise
In the previous quarter, SAPIEN M3 received FDA approval for the treatment of mitral regurgitation (MR). We expect this development to have contributed to the company’s top-line growth.
The Zacks Consensus Estimate for the TMTT business’ revenues is pegged at $161 million, implying a 39.8% improvement from the year-ago period’s level.
Edwards’ Surgical Structural Heart might have delivered a strong performance in the to-be-reported quarter, driven by global adoption of its premium RESILIA portfolio, including MITRIS, INSPIRIS and KONECT.
The Zacks Consensus Estimate for the segment’s revenues is pegged at $267.2 million, suggesting a modest 6.5% rise from the year-ago quarter’s reported figure.
Earnings Whispers for Edwards
Per our proven model, stocks with a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold), along with a positive Earnings ESP, have a higher chance of beating estimates, which is not the case here, as you can see below:
Earnings ESP: Edwards has an Earnings ESP of -0.65%. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Here are some medical stocks worth considering, as these have the right combination of elements to post an earnings beat this time around:
Agenus (AGEN - Free Report) has an Earnings ESP of +7.69% and a Zacks Rank #1 at present. The company is expected to release first-quarter 2026 results soon.
AGEN’s earnings surpassed estimates in two of the trailing four quarters and missed in the other two, the average surprise being 31.42%. The Zacks Consensus Estimate for first-quarter EPS implies an increase of 289.3% from the year-ago quarter’s figure.
Biogen (BIIB - Free Report) has an Earnings ESP of +3.26% and a Zacks Rank #2 at present. The company is slated to release first-quarter 2026 results soon.
BIIB’s earnings surpassed estimates in three of the trailing four quarters and missed in one, the average surprise being 19.8%. The Zacks Consensus Estimate for first-quarter EPS implies a year-over-year decrease of 0.3%.
The Ensign Group (ENSG - Free Report) has an Earnings ESP of +1.12% and a Zacks Rank #2 at present. The company is expected to release first-quarter 2026 results soon.
ENSG’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 2.9%. The Zacks Consensus Estimate for first-quarter EPS suggests a 17.7% year-over-year improvement.
Zacks' 7 Best Strong Buy Stocks (New Research Report)
Valued at $99, click below to receive our just-released report
predicting the 7 stocks that will soar highest in the coming month.
View the Zacks #1 Rank List
Image: Bigstock
Edwards Lifesciences' Q1 Earnings on Deck: Here's What to Expect
Key Takeaways
Edwards Lifesciences Corp. (EW - Free Report) is scheduled to report first-quarter 2026 results on April 23, after market close.
In the last reported quarter, the company’s adjusted earnings per share of 58 cents missed the Zacks Consensus Estimate by 6.45%. Its earnings beat estimates in three of the trailing four quarters and missed in one, the average surprise being 5.46%.
EW’s Q1 Estimates
The Zacks Consensus Estimate for revenues is pegged at $1.59 billion, suggesting 12.9% growth from the year-ago reported figure.
The Zacks Consensus Estimate for earnings is pinned at 72 cents per share, indicating a 12.5% rise from the year-ago reported number.
Estimate Revision Trend Ahead of Edwards’ Q1 Earnings
Estimates for earnings have remained unchanged at 72 cents per share in the past 30 days.
Here’s a brief overview of the company’s progress ahead of this announcement.
Factors at Play
In the first quarter of 2026, the Transcatheter Aortic Valve Replacement (“TAVR”) arm is likely to have delivered strong performance, supported by clinicians' elevated focus on SAPIEN therapy and proactive disease management for patients with severe aortic stenosis.
In the United States, growth appears to have been driven by a strong focus on the timely treatment of patients with severe aortic stenosis, supported by a growing body of high-quality clinical evidence for the SAPIEN platform and increased adoption of the company’s SAPIEN 3 Ultra RESILIA. Progress is also likely to have been supported by CMS’ decision to formally reconsider the NCD for TAVR.
In the previous quarter, results in Europe reflected solid underlying procedure growth and consistent regional execution, supported by updated European Society of Cardiology and European Association for Cardiothoracic Surgery guidelines that are reshaping clinical discussions. We expect these trends to have persisted in the first quarter as well.
Per the Zacks Consensus Estimate, TAVR sales are expected to be $1.16 billion, implying a 10.5% year-over-year increase.
In the Transcatheter Mitral and Tricuspid Therapies (“TMTT”) segment, strength in the portfolio of repair and replacement technologies for both Mitral and Tricuspid valves is likely to have supported Edwards’ performance in first-quarter 2026. The PASCAL and EVOQUE systems are expected to have gained traction globally.
Also, with the addition of SAPIEN M3 mitral valve replacement system — the first transcatheter therapy utilizing a transseptal approach — Edwards is uniquely positioned to have met the broad and diverse needs of patients with mitral and tricuspid valve diseases.
Edwards Lifesciences Corporation Price and EPS Surprise
Edwards Lifesciences Corporation price-eps-surprise | Edwards Lifesciences Corporation Quote
In the previous quarter, SAPIEN M3 received FDA approval for the treatment of mitral regurgitation (MR). We expect this development to have contributed to the company’s top-line growth.
The Zacks Consensus Estimate for the TMTT business’ revenues is pegged at $161 million, implying a 39.8% improvement from the year-ago period’s level.
Edwards’ Surgical Structural Heart might have delivered a strong performance in the to-be-reported quarter, driven by global adoption of its premium RESILIA portfolio, including MITRIS, INSPIRIS and KONECT.
The Zacks Consensus Estimate for the segment’s revenues is pegged at $267.2 million, suggesting a modest 6.5% rise from the year-ago quarter’s reported figure.
Earnings Whispers for Edwards
Per our proven model, stocks with a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold), along with a positive Earnings ESP, have a higher chance of beating estimates, which is not the case here, as you can see below:
Earnings ESP: Edwards has an Earnings ESP of -0.65%. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Zacks Rank: The company currently carries a Zacks Rank #2. You can see the complete list of today’s Zacks #1 Rank stocks here.
Top MedTech Picks
Here are some medical stocks worth considering, as these have the right combination of elements to post an earnings beat this time around:
Agenus (AGEN - Free Report) has an Earnings ESP of +7.69% and a Zacks Rank #1 at present. The company is expected to release first-quarter 2026 results soon.
AGEN’s earnings surpassed estimates in two of the trailing four quarters and missed in the other two, the average surprise being 31.42%. The Zacks Consensus Estimate for first-quarter EPS implies an increase of 289.3% from the year-ago quarter’s figure.
Biogen (BIIB - Free Report) has an Earnings ESP of +3.26% and a Zacks Rank #2 at present. The company is slated to release first-quarter 2026 results soon.
BIIB’s earnings surpassed estimates in three of the trailing four quarters and missed in one, the average surprise being 19.8%. The Zacks Consensus Estimate for first-quarter EPS implies a year-over-year decrease of 0.3%.
The Ensign Group (ENSG - Free Report) has an Earnings ESP of +1.12% and a Zacks Rank #2 at present. The company is expected to release first-quarter 2026 results soon.
ENSG’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 2.9%. The Zacks Consensus Estimate for first-quarter EPS suggests a 17.7% year-over-year improvement.